Loading...
Myasthenia gravis (MG), an autoimmune disease that affects synaptic transmission at the neuromuscular junction, is classified into different subtypes on the basis of type of antibodies and manifestation of the disease, such as generalized or ocular myasthenia. Most patients with a generalized myasthenia (gMG) have autoantibodies to acetylcholine receptors (AChRs), which produce internalization and degradation of the receptors, thereby blocking synaptic transmission. AChRs also activate complement, which damages the postsynaptic membrane at the neuromuscular junction. A non-FDA-approved drug, zilucoplan, blocks the complement system. To test the efficacy of zilucoplan in moderate to severe AChR antibody–positive patients with gMG, researcher…